Back to today’s briefing

Story perspectives

New Antiviral Boosts Health in HIV Patients, But Costly

3/23/2025

27 2

Summary

Story summary

A groundbreaking study at CROI 2025 revealed that letermovir, an antiviral for cytomegalovirus (CMV), significantly reduces inflammation and boosts CD4 T-cell counts in HIV-positive patients undergoing antiretroviral therapy. Lead researcher Sara Gianella Weibel emphasized its promise for improving aging-related health, though its steep price hampers widespread adoption.

1 of 1

Story summary

A groundbreaking study at CROI 2025 revealed that letermovir, an antiviral for cytomegalovirus (CMV), significantly reduces inflammation and boosts CD4 T-cell counts in HIV-positive patients undergoing antiretroviral therapy. Lead researcher Sara Gianella Weibel emphasized its promise for improving aging-related health, though its steep price hampers widespread adoption.